Rationale for combining PARP inhibitors with topotecan or irinotecan: taking advantage of the alternative DNA repair pathways involving XPF-ERCC1 and PARP-TDP1

被引：0

|

作者：

Zhang, Yongwei ^{[1
]}

Regairaz, Marie ^{[1
]}

Seiler, Jennifer ^{[1
]}

Agama, Keli ^{[1
]}

Doroshow, James ^{[1
]}

Pommier, Yves ^{[1
]}

机构：

[1] NCI, Bethesda, MD 20892 USA

来源：

CANCER RESEARCH | 2012年 / 72卷

关键词：

D O I：

10.1158/1538-7445.AM2012-4691

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4691

引用

收藏

页数：2

相关论文

共 3 条

[1] Optimised oligonucleotide substrates to assay XPF-ERCC1 nuclease activity for the discovery of DNA repair inhibitors
Thomas, Adam M.
Brolih, Sanja
McGouran, Joanna F.
El-Sagheer, Afaf H.
Ptchelkine, Denis
Jones, Morgan
McDonald, Neil Q.
McHugh, Peter J.
Brown, Tom
CHEMICAL COMMUNICATIONS, 2019, 55 (78) : 11671 - 11674
[2] Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells
Zhang, Yong-Wei
Regairaz, Marie
Seiler, Jennifer A.
Agama, Keli K.
Doroshow, James H.
Pommier, Yves
NUCLEIC ACIDS RESEARCH, 2011, 39 (09) : 3607 - 3620
[3] Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
Chen, Xian
Yang, Dong
Carey, Jason P. W.
Karakas, Cansu
Albarracin, Constance
Sahin, Aysegul A.
Arun, Banu K.
Guray Durak, Merih
Li, Mi
Kohansal, Mehrnoosh
Bui, Tuyen N.
Ha, Min-Jin
Hunt, Kelly K.
Keyomarsi, Khandan
CANCERS, 2021, 13 (07)